Goldman's view on earnings, page-2

First 2 Last

Share
Profile

Follow
Weehawken

2,398 Posts.

300

24/08/23

22:01

Post #: 69536915
Share

Originally posted by Pout: ↑

I thought it would be beneficial to know Goldman Sachs' view of fy23 earnings and how it stacks up to share holder expectations. I would appreciate all insights for discussion. I'll start off by saying that I believe this forecast is low as it doesn't take into account any of the revenue generated from cash on hand and implies low spot prices and higher costs throughout the fy, which has not been the case. Nevertheless below is an extract of how GS sees the report going on Tuesday:

According to a note out of Goldman Sachs, its analysts are expecting Lynas to deliver a soft result compared to what it reported a year ago.The broker is expecting revenue of $765 million for the 12 months, down 16.8% year on year. This reflects a 25% decline in its average selling price to US$33 per kg.Goldman is also expecting Lynas’ costs to go in the wrong direction in FY 2023. It is forecasting cash costs of A$25 per kg, up 25% year on year.The sum of the above means an underlying EBITDA margin of 47%, down from 65% a year earlier. As you would expect, if this is accurate, it is going to crunch Lynas’ earnings.Goldman expects the company’s underlying EBITDA to fall 40% to $362 million and its underlying profits to drop 48.2% to $280 million.No dividend is expected to be paid for FY 2023.

glta

Expand

These guys want us to believe in a static world so they can buy our shares cheap when feed on Kal, Malaysian decision, more US news, move the price up. We live in a dynamic world! This runs against Merrill price target. $1B cash in the bank would seem to buy a lot of buffer to these events moving forward.

LYC Price at posting: $7.06 Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

First 2 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $9.02		Change -0.185(2.01%)		Mkt cap ! $8.423B

Open	High	Low	Value	Volume
$9.44	$9.44	$8.97	$23.89M	2.625M

Buyers (Bids)

No.	Vol.	Price($)
47	11267	$9.01

Sellers (Offers)

Price($)	Vol.	No.
$9.02	10699	32

View Market Depth

No.	Vol.	Price($)
7	2042	9.010
24	11227	9.000
20	10875	8.990
12	9390	8.980
13	18442	8.970

Price($)	Vol.	No.
9.020	7485	25
9.030	10805	21
9.040	19363	15
9.050	18152	14
9.060	8790	9

Last trade - 13.06pm 27/06/2025 (20 minute delay)

LYC (ASX) Chart

Goldman's view on earnings, page-2

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Goldman's view on earnings, page-2

Top Stories

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News